Perinatal anxiety and depressive symptoms in women with preeclampsia: A cohort study of placental dysfunction and neuroendocrine correlates

Table 6 Multivariable regression models for psychological symptom scores, β (95%CI)

Predictor	Edinburgh Postnatal Depression Scale score	Generalized Anxiety Disorder-7 score	State-Trait Anxiety Inventory-State score
Soluble fms-like tyrosine kinase-1/placental growth factor ratio (per 100 units)	0.28 (0.12-0.44)b	0.25 (0.09-0.41)b	0.23 (0.08-0.38)b
Morning cortisol (nmol/L)	0.31 (0.16-0.46)c	0.27 (0.12-0.42)b	0.29 (0.14-0.44)c
Severe features (yes vs no)	0.35 (0.19-0.51)c	0.32 (0.16-0.48)c	0.30 (0.14-0.46)c
Early-onset preeclampsia (yes vs no)	0.18 (0.02-0.34)a	0.16 (-0.01 to 0.33)	0.14 (-0.03 to 0.31)
Nulliparity (yes vs no)	0.22 (0.06-0.38)a	0.19 (0.03-0.35)a	0.17 (0.01-0.33)a
Adverse outcomes (yes vs no)	0.24 (0.08-0.40)b	0.21 (0.05-0.37)a	0.20 (0.04-0.36)a
Pre-pregnancy body mass index (kg/m2)	0.12 (-0.04 to 0.28)	0.10 (-0.06 to 0.26)	0.09 (-0.07 to 0.25)
Model R2 (adjusted)	0.524	0.478	0.441

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

Adverse outcomes were defined as a composite of preterm birth, fetal growth restriction, or neonatal intensive care unit admission. Models adjusted for maternal age, education, and gestational age at enrollment.